Selective PDE4D inhibitor shows potential to treat Fragile X autism spectrum disorder

November 7, 2017, Tetra Discovery Partners

New preclinical research suggests the potential utility of BPN14770, a selective PDE4D inhibitor currently under development by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer's disease, in the treatment of Fragile X Syndrome (FXS) and possibly other autism spectrum disorders.

Daily treatment of adult male fmr1 C57B16 knockout (a standard FXS animal model) for 14 days reduced hyperarousal, and improved social interactions and increased natural behaviors such as nesting and marble burying compared to control FXS mice that received a placebo. At the same time, there was no deleterious effect on behavioral scores in normal wild-type mice treated with BPN14770. The behavioral benefits of BPN14770 in the FXS mice endured for two weeks after drug washout. Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology; this finding, combined with the 11 hour half-life of BPN14770 in mice, suggests that the enduring treatment benefits of BPN14770 were not due to slow washout of the drug.

The new research was published online today in Scientific Reports, an online, open-access primary research publication from the publishers of Nature by Tetra Discovery Partners and the company's research collaborators.

"This preclinical study strongly supports PDE4D as a therapeutic target for the treatment of FXS," said Mark E. Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra Discovery Partners. "We have already demonstrated evidence of human safety and tolerability for BPN14770 in a Phase 1 study in healthy young and elderly volunteers. This research suggests BPN14770 may also have utility in the treatment of FXS, which is associated with a spectrum of neuropsychiatric symptoms, mild to severe cognitive impairment and intellectual disability, and potentially also find use in the treatment of other conditions on the autism spectrum."

"The results from these studies are very promising," commented Michael Tranfaglia, M.D., Medical Director and Chief Scientific Officer of the FRAXA Research Foundation. "Inhibition of PDE4 has been validated as a treatment strategy by many research groups in the Fragile X field. However, the current study demonstrates the enhanced therapeutic potential of PDE4D inhibition with BPN14770, which shows the ability to rescue major Fragile X phenotypes not only in acute dosing, but in chronic dosing as well.

"Furthermore, the significant carryover of BPN14770 effects, even two weeks after suggests this drug candidate has genuine long-term beneficial effects on Fragile X pathology," Dr. Tranfaglia continued. "Additionally, tolerance has been a major problem with other drug classes studied as potential treatments for Fragile X syndrome, such as mGluR5 NAMs and GABA-B agonists, but no tolerance was been seen in studies with BPN14770. The selective nature of this compound, which targets only PDE4D, also greatly improves the tolerability of the drug over past-studied, general PDE4 inhibitors, which should facilitate clinical trials in this difficult-to-treat population."

Explore further: New memory drug moves into Phase 1 clinical study

More information: Mark E. Gurney et al, Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D), Scientific Reports (2017). DOI: 10.1038/s41598-017-15028-x

Related Stories

New memory drug moves into Phase 1 clinical study

January 1, 2016
An experimental drug that may improve memory is now being tested in a Phase 1 safety trial. The compound, BPN14770, was developed by Tetra Discovery Partners, with support from the NIH Blueprint Neurotherapeutics Network, ...

Promise seen in possible treatment for autism spectrum disorder

November 1, 2017
Human chromosome 16p11.2 deletion syndrome is caused by the absence of about 27 genes on chromosome 16. This deletion is characterized by intellectual disability; impaired language, communication, and socialization skills; ...

Diabetes drug may help symptoms of autism associated condition

May 15, 2017
A widely used diabetes medication could help people with a common inherited form of autism, research shows.

Brain study reveals clues to treating Fragile X syndrome

August 3, 2017
Scientists have discovered how the brain can self-correct disruptions in processing, pointing the way towards possible new treatments for autism and intellectual disability.

Treatment window for Fragile X likely doesn't close after childhood

March 20, 2017
Brain samples from humans show that the treatment window for Fragile X syndrome likely remains open well into maturity after childhood, when previous tests with mice indicated it might close, according to a new Drexel University-led ...

New role for fragile X protein could offer clues for treatment

September 28, 2017
The protein behind fragile X syndrome acts as a genetic conductor, orchestrating a symphony of genes that help shape DNA's 3-D structure.

Recommended for you

Therapeutic antibodies protected nerve–muscle connections in a mouse model of Lou Gehrig's disease

February 20, 2018
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, causes lethal respiratory paralysis within several years of diagnosis. There are no effective treatments to slow or halt this devastating disease. Mouse ...

Brain liquefaction after stroke is toxic to surviving brain: study

February 20, 2018
Scientists have known for years that the brain liquefies after a stroke. If cut off from blood and oxygen for a long enough period, a portion of the brain will die, slowly morphing from a hard, rubbery substance into liquid ...

Every experience that the brain perceives is unique

February 20, 2018
Neuronal activity in the prefrontal cortex represents every experience as "novel." The neurons adapt their activity accordingly, even if the new experience is very similar to a previous one. That is the main finding of a ...

Brain aging may begin earlier than expected

February 20, 2018
Physicists have devised a new method of investigating brain function, opening a new frontier in the diagnoses of neurodegenerative and ageing related diseases.

Brain immune system is key to recovery from motor neuron degeneration

February 20, 2018
The selective demise of motor neurons is the hallmark of Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS). Yet neurologists have suspected there are other types of brain cells involved in the progression ...

Electrical implant reduces 'invisible' symptoms of man's spinal cord injury

February 19, 2018
An experimental treatment that sends electrical currents through the spinal cord has improved "invisible" yet debilitating side effects for a B.C. man with a spinal cord injury.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.